Shift from first generation antipsychotics to olanzapine may improve health-related quality of life of stable but residually symptomatic schizophrenic outpatients: A prospective, randomized study

2008 ◽  
Vol 24 (04) ◽  
pp. 399-402 ◽  
Author(s):  
Grigori Joffe ◽  
Harri Sintonen ◽  
Björn Appelberg

Objectives:The aim of this study was to elucidate, whether shift from first generation antipsychotics (FGA) to olanzapine can affect health-related quality of life (HRQoL) of residually symptomatic schizophrenic outpatients.Methods:Patients were randomized to either olanzapine or to continuation on their FGA. The 15D-measured HRQoL at baseline and end-point (after 12 weeks) was compared.Results:Patients (n= 21) randomized to olanzapine achieved better HRQoL than those (n= 21) who continued on their FGA. This difference on the 15D (0.048 on a 0–1 scale;p= .037) was clinically important and comparable to that resulting from common surgical interventions, for example, hip or knee replacement.Conclusions:HRQoL of stable outpatients with residual symptoms or adverse effects may improve substantially after shift from FGAs to olanzapine.

Author(s):  
Jonathan I. Silverberg ◽  
Emma Guttman-Yassky ◽  
Melinda Gooderham ◽  
Margitta Worm ◽  
Stephanie Rippon ◽  
...  

Reumatismo ◽  
2019 ◽  
Vol 71 (2) ◽  
pp. 62-67
Author(s):  
T. Schioppo ◽  
L. Scalone ◽  
P. Cozzolino ◽  
L. Mantovani ◽  
G. Cesana ◽  
...  

Systemic sclerosis (SSc)-related Raynaud’s phenomenon (RP) and digital ulcers (DU) can impair health-related quality of life (HRQoL). The aim of our study was to estimate HRQoL in SSc patients treated with two different intravenous (IV) iloprost (ILO) regimens and in patients not treated with IV ILO. 96 consecutive SSc patients were enrolled in a pragmatic, prospective and non-randomized study, and divided into 3 groups: not requiring therapy with IV ILO (N=52), IV ILO once monthly (N=24) or IV ILO for 5 consecutive days every 3 months (N=20). Patients were followed up for three months. We assessed HRQoL using the generic preference-based questionnaire EQ-5D-5L. We conducted multiple regression analyses to estimate, in each treatment group, the mean general health (GH) and the mean utility index of the EQ-5D-5L, adjusting for possible confounders. The mean adjusted utility index and GH score, after three months’ follow-up, were not different in the three groups: IV ILO was able to make patients requiring IV ILO similar to those not requiring it. Moreover, there was no difference in this model between the two ILO regimens (1 day monthly vs 5 consecutive days every 3 months). The two different IV ILO regimens (the most appropriate regimen was decided according to patients’ characteristics and needs) were able to stabilize HRQoL in RP secondary to SSc non-adequately controlled by oral therapy.


2012 ◽  
Vol 34 (23) ◽  
pp. 1971-1977 ◽  
Author(s):  
Petri Salo ◽  
Niina Ylönen-Käyrä ◽  
Arja Häkkinen ◽  
Hannu Kautiainen ◽  
Esko Mälkiä ◽  
...  

AIDS ◽  
1999 ◽  
Vol 13 (13) ◽  
pp. 1727-1735 ◽  
Author(s):  
Xavier Badia ◽  
Daniel Podzamczer ◽  
Margarida Garcia ◽  
Carmen López-Lavid C ◽  
Ezequiel Consiglio

2021 ◽  
Author(s):  
Tamara Cristine de Paula ◽  
Tereza Raquel de Melo Alcântara-Silva ◽  
Leonardo Francisco Citon ◽  
Celmo Celeno Porto

Abstract Background: Parkinson's disease (PD) is the second most common neurodegenerative, progressive and disabling disease affecting the elderly population, with by motor and non-motor symptoms that interfere with the Health-Related Quality of Life (HRQoL) of this population. Currently, there are still no resources to cure the disease, so the main treatment method used to reduce symptoms is based initially on pharmacological therapy, and in some cases, surgery is recommended. However, some unconventional interventions have been used, showing good results for the improvement of symptoms that also include HRQoL. Therefore, this investigation aimed to identify non-pharmacological or non-surgical interventions, in randomized clinical studies (RCTs) and their effectiveness in improving the HRQoL of people with PD.Methods: Systematic review, guided by the PRISMA method, using the SciELO, MEDLINE / PubMed, Cochrane Library, Web of Science, Scopus, and Brazilian Digital Library of Theses and Dissertations databases - BDTD, through CAFe Access on the CAPES / MEC Journals portal. "Quality of Life" - "Parkinson’s Disease" - "Randomized Controlled Trial", were the keywords used. Articles were selected by 2 independent reviewers using a third for doubts / discrepancies. Articles published until October 2020, in languages English, Portuguese and Spanish, RCTs, with non-pharmacological or non-surgical interventions, population diagnosed with PD, at any age or stage of the disease will be included. A narrative synthesis will be used to summarize the results and discussion, as well as a methodological evaluation of the RCTs using Cochrane Collaboration's risk of bias tool.Discussion: This review will identify the effectiveness of non-pharmacological and non-surgical interventions aimed at improving the HRQoL of people with PD, based on assessment instruments related to the proposed theme, based on RCT. Therefore, the findings show the current panorama of studies performed, discussion about their clinical applicability, as well as suggestions for improvements of future trials.Registration of Systematic Review: CRD42021221383


Sign in / Sign up

Export Citation Format

Share Document